The early effect of dapagliflozin on diastolic function parameters in patients with mid range and reduced ejection fraction heart failure

Cardiovascular mortality and hospitalisation rates were greatest among heart failure (HF) patients with reduced ejection fraction (HFrEF) according to clinical trial data. Treatment of heart failure with sodium-glucose transporter-2 inhibitors (SGLT2i) has recently made significant strides [1]. Even in patients with HFrEF, LV diastolic dysfunction was a separate predictor of outcome [2]. It is essential to identify structural abnormalities using echocardiography since they have been linked to prognosis in HF and DM patients [3]. Both diabetic and non-diabetes patients with HF have had their risk of death and hospital readmission decreased by SGLT2is, according to large-scale randomised studies and meta-analyses [4]. These are part of the global guidelines for the treatment of heart failure (HF) at the intermediate assessment level [5]. Some theories suggest that SGLT2is exerts its cardioprotective effects by reversing cardiac remodelling [6] and restoring systolic and diastolic function [7].Some theories suggest that SGLT2is exerts its cardioprotective effects by reversing cardiac remodelling and restoring systolic and diastolic function